GE HealthCare Announced that the FDA Approved Expanded Indications for Vizamyl Pet Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients
On June 24, 2025, GE HealthCare announced that the U.S. Food and Drug Administration (FDA) approved an updated label for its PET imaging agent Vizamyl™ (flutemetamol F 18 injection), marking a significant advancement in Alzheimer’s disease diagnosis and management. The revised label, now effective, expands the agent’s indications for use by introducing quantification capabilities that allow for a more continuous and objective measurement of beta-amyloid levels in the brain.
Th...
